(4R)-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,3-oxazolidin-2-one | 265992-56-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4R)-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,3-oxazolidin-2-one
• 英文别名: (R)-4-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)oxazolidin-2-one
• CAS: 265992-56-1
• 化学式: C₈H₁₃NO₄
• 分子量: 187.196
• InChiKey: OSOIXNHNDCQLOM-PHDIDXHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4R)-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,3-oxazolidin-2-one 在 甲醇 、 乙酰氯 作用下， 反应 4.0h， 以93%的产率得到(4R)-4-[(1S)-1,2-dihydroxyethyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Transition state analogue inhibitors of human methylthioadenosine phosphorylase and bacterial methylthioadenosine/S-adenosylhomocysteine nucleosidase incorporating acyclic ribooxacarbenium ion mimics

  摘要：

  Several acyclic hydroxy-methylthio-amines with 3-5 carbon atoms were prepared and coupled via a methylene link to 9-deazaadenine. The products were tested for inhibition against human MTAP and Escherichia coli and Neisseria meningitidis MTANs and gave K-i values as low as 0.23 nM. These results were compared to those obtained with 1st and 2nd generation inhibitors (1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol (MT-Immucillin-A, 3) and (3R,4S)-1-[9-deazaadenin-9-yl)methyl]3-hydroxy-4-methylthiomethylpyrrolidine (MT-DADMe-Immucillin-A, 4). The best inhibitors were found to exhibit binding affinities of approximately 2- to 4-fold those of 3 but were significantly weaker than 4. Cleavage of the 2,3 carbon-carbon bond in MT-Immucillin-A (3) gave an acyclic product (79) with a 21,500 fold loss of activity against E. coli MTAN. In another case, N-methylation of a side chain secondary amine resulted in a 250-fold loss of activity against the same enzyme [(+/-)-65 vs (+/-)-68]. The inhibition results were also contrasted with those acyclic derivatives previously prepared as inhibitors for a related enzyme, purine nucleoside phosphorylase (PNP), where some inhibitors in the latter case were found to be more potent than their cyclic counterparts. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.006
• 作为产物：
  描述：

  4,4-二甲基-3,5,8-三氧杂双环[5,1,0]辛烷 在 palladium on activated charcoal 甲烷磺酸 、 氢气 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 异丙醇 、 丙酮 为溶剂， 40.0 ℃ 、1.5 MPa 条件下， 反应 41.33h， 生成 (4R)-4-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  WO2008/30118

  摘要：

  公开号：

文献信息

• ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
  申请人：Clinch Keith

  公开号：US20110046167A1

  公开（公告）日：2011-02-24

  The present invention relates to compounds of the general formula (I) which are inhibitors of 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

  本发明涉及一般公式（I）的化合物，它们是5'-甲基硫腺苷磷酸化酶或5'-甲基硫腺苷核苷酸酶的抑制剂。本发明还涉及使用这些化合物治疗希望抑制5'-甲基硫腺苷磷酸化酶或5'-甲基硫腺苷核苷酶的疾病或病况，包括癌症，并且涉及含有这些化合物的药物组合物。
• ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
  申请人：INDUSTRIAL RESEARCH LIMITED

  公开号：EP2049543A1

  公开（公告）日：2009-04-22
• US8383636B2
  申请人：——

  公开号：US8383636B2

  公开（公告）日：2013-02-26
• [EN] ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE<br/>[FR] INHIBITEURS AMINES ACYCLIQUES DE LA 5'-MÉTHYLTHIOADÉNOSINE PHOSPHORYLASE ET NUCLÉOSIDASE
  申请人：IND RES LTD

  公开号：WO2008030118A1

  公开（公告）日：2008-03-13

  [EN] The present invention relates to compounds of the general formula (I) which are inhibitors of 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5'-methylthioadenosine phosphorylase or 5'-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.
  [FR] L'invention concerne des composés de la formule générale (I) qui sont des inhibiteurs de la 5'-méthylthioadénosine phosphorylase ou de la 5'-méthylthioadénosine nucléosidase. L'invention se rapporte également à l'utilisation des composés précités dans le traitement de maladies ou états dans lesquels il est souhaitable d'inhiber la 5'-méthylthioadénosine phosphorylase ou la 5'-méthylthioadénosine nucléosidase, y compris le cancer, et à des compositions pharmaceutiques contenant lesdits composés.
• Transition state analogue inhibitors of human methylthioadenosine phosphorylase and bacterial methylthioadenosine/S-adenosylhomocysteine nucleosidase incorporating acyclic ribooxacarbenium ion mimics
  作者：Keith Clinch、Gary B. Evans、Richard F.G. Fröhlich、Shivali A. Gulab、Jemy A. Gutierrez、Jennifer M. Mason、Vern L. Schramm、Peter C. Tyler、Anthony D. Woolhouse

  DOI：10.1016/j.bmc.2012.07.006

  日期：2012.9

  Several acyclic hydroxy-methylthio-amines with 3-5 carbon atoms were prepared and coupled via a methylene link to 9-deazaadenine. The products were tested for inhibition against human MTAP and Escherichia coli and Neisseria meningitidis MTANs and gave K-i values as low as 0.23 nM. These results were compared to those obtained with 1st and 2nd generation inhibitors (1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol (MT-Immucillin-A, 3) and (3R,4S)-1-[9-deazaadenin-9-yl)methyl]3-hydroxy-4-methylthiomethylpyrrolidine (MT-DADMe-Immucillin-A, 4). The best inhibitors were found to exhibit binding affinities of approximately 2- to 4-fold those of 3 but were significantly weaker than 4. Cleavage of the 2,3 carbon-carbon bond in MT-Immucillin-A (3) gave an acyclic product (79) with a 21,500 fold loss of activity against E. coli MTAN. In another case, N-methylation of a side chain secondary amine resulted in a 250-fold loss of activity against the same enzyme [(+/-)-65 vs (+/-)-68]. The inhibition results were also contrasted with those acyclic derivatives previously prepared as inhibitors for a related enzyme, purine nucleoside phosphorylase (PNP), where some inhibitors in the latter case were found to be more potent than their cyclic counterparts. (C) 2012 Elsevier Ltd. All rights reserved.